Journal Mobile Options
Table of Contents
Vol. 45, No. 5, 2012
Issue release date: August 2012
Section title: Original Paper
Psychopathology 2012;45:276–285
(DOI:10.1159/000336729)

Evaluating Depressive Symptoms in Schizophrenia: A Psychometric Comparison of the Calgary Depression Scale for Schizophrenia and the Hamilton Depression Rating Scale

Schennach R. · Obermeier M. · Seemüller F. · Jäger M. · Schmauss M. · Laux G. · Pfeiffer H. · Naber D. · Schmidt L.G. · Gaebel W. · Klosterkötter J. · Heuser I. · Maier W. · Lemke M.R. · Rüther E. · Klingberg S. · Gastpar M. · Riedel M. · Möller H.-J.
aDepartment of Psychiatry and Psychotherapy, Ludwig-Maximilians-University, Munich, bPsychiatric Clinic, District Hospital, Augsburg, cPsychiatric Clinic, Inn-Salzach Hospital, Wasserburg/Inn, dPsychiatric Clinic, Isar-Amper Hospital, Munich-Haar, eDepartment of Psychiatry and Psychotherapy, University of Hamburg, Hamburg, fDepartment of Psychiatry and Psychotherapy, University of Mainz, Mainz, gDepartment of Psychiatry and Psychotherapy, Medical Faculty, Heinrich-Heine-University, Düsseldorf, hDepartment of Psychiatry and Psychotherapy, University of Cologne, Cologne, iDepartment of Psychiatry and Psychotherapy, Charite Berlin, Campus Benjamin Franklin, Berlin, jDepartment of Psychiatry and Psychotherapy, University of Bonn, Bonn, kDepartment of Psychiatry, Alsterdorf Hospital, Hamburg, lDepartment of Psychiatry and Psychotherapy, University of Göttingen, Göttingen, mDepartment of Psychiatry and Psychotherapy, University of Tübingen, Tübingen, nDepartment of Psychiatry and Psychotherapy, University of Essen, Essen, and oPsychiatric Clinic, Vinzenz von Paul Hospital, Rottweil, Germany

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restriction apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Automatic perpetual access to all articles of the subscribed year(s)
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: 12/14/2010 12:29:19 PM
Accepted: 1/15/2012
Published online: 7/12/2012

Number of Print Pages: 10
Number of Figures: 1
Number of Tables: 8

ISSN: 0254-4962 (Print)
eISSN: 1423-033X (Online)

For additional information: http://www.karger.com/PSP

Abstract

Background: The aim of this study was to compare two measures of depression in patients with schizophrenia and schizophrenia spectrum disorder, including patients with delusional and schizoaffective disorder, to conclude implications for their application. Sampling and Methods: A total of 278 patients were assessed using the Calgary Depression Scale for Schizophrenia (CDSS) and the Hamilton Depression Rating Scale (HAMD-17). The Positive and Negative Syndrome Scale (PANSS) was also applied. At admission and discharge, a principal component analysis was performed with each depression scale. The two depression rating scales were furthermore compared using correlation and regression analyses. Results: Three factors were revealed for the CDSS and HAMD-17 factor component analysis. A very similar item loading was found for the CDSS at admission and discharge, whereas results of the loadings of the HAMD-17 items were less stable. The first two factors of the CDSS revealed correlations with positive, negative and general psychopathology. In contrast, multiple significant correlations were found for the HAMD-17 factors and the PANSS subscores. Multiple regression analyses demonstrated that the HAMD-17 accounted more for the positive and negative symptom domains than the CDSS. Conclusions: The present results suggest that compared to the HAMD-17, the CDSS is a more specific instrument to measure depressive symptoms in schizophrenia and schizophrenia spectrum disorder, especially in acutely ill patients.


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: 12/14/2010 12:29:19 PM
Accepted: 1/15/2012
Published online: 7/12/2012

Number of Print Pages: 10
Number of Figures: 1
Number of Tables: 8

ISSN: 0254-4962 (Print)
eISSN: 1423-033X (Online)

For additional information: http://www.karger.com/PSP


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.